Can You Increase Jardiance from 25mg?
No, you cannot increase Jardiance beyond 25 mg—this is the maximum approved dose for glycemic control. 1
The Dosing Reality
The FDA-approved dosing for Jardiance (empagliflozin) is straightforward:
- Starting dose: 10 mg once daily
- Maximum dose: 25 mg once daily for additional glycemic control in patients tolerating the 10 mg dose 1
Since your patient is already on 25 mg (the ceiling dose), dose escalation is not an option.
What To Do Instead
When A1c remains elevated on maximum-dose Jardiance, you must add a different medication class rather than increase the SGLT2 inhibitor dose. The 2025 ADA guidelines provide clear direction 2:
First Priority: Add a GLP-1 Receptor Agonist
Add a GLP-1 RA (like semaglutide, dulaglutide, or liraglutide) to the regimen. This combination offers:
- A1c reduction of 1-2% when added to existing therapy 2
- Complementary mechanisms (SGLT2i works renally; GLP-1 RA works via incretin pathways)
- Additional cardiovascular and renal benefits 2
- Weight loss benefits (intermediate to very high) 2
- Low hypoglycemia risk 2
Alternative: Consider Dual GIP/GLP-1 RA
Tirzepatide (dual GIP and GLP-1 RA) provides even greater glycemic efficacy (very high glucose-lowering effect) with similar cardiovascular-renal benefits 2.
If GLP-1 RA Not Feasible: Add Basal Insulin
If GLP-1 RA therapy is contraindicated or not tolerated, initiate basal insulin (NPH or long-acting analog) 2. However, this comes with:
- Higher hypoglycemia risk
- Potential weight gain
- Less favorable cardiovascular profile compared to GLP-1 RAs
Critical Pitfalls to Avoid
Do NOT combine GLP-1 RA with DPP-4 inhibitors (like sitagliptin)—there is no added glucose-lowering benefit beyond the GLP-1 RA alone, and you're just adding cost and potential side effects 2.
Do NOT delay treatment intensification. Therapeutic inertia worsens long-term outcomes. Each new class added to existing therapy typically lowers A1c by 0.7-1.0% for oral agents, or 1-2% for GLP-1 RAs 2.
Check Renal Function First
Before adding any medication, verify the patient's eGFR 2, 1:
- Jardiance provides minimal glucose-lowering benefit below eGFR 45 mL/min/1.73 m² (though continue for cardiovascular/renal protection) 2
- If eGFR <30 mL/min/1.73 m², Jardiance is not recommended for glycemic control 1
- GLP-1 RAs (particularly semaglutide, dulaglutide, liraglutide) work effectively regardless of kidney function 2
The Bottom Line Algorithm
- Confirm patient is on 25 mg Jardiance (maximum dose reached)
- Check eGFR to ensure Jardiance is still appropriate
- Add GLP-1 RA as first-line intensification (semaglutide, dulaglutide, or liraglutide preferred for CV/renal benefits)
- If GLP-1 RA contraindicated: Consider dual GIP/GLP-1 RA (tirzepatide) or basal insulin
- Discontinue any DPP-4 inhibitor if starting GLP-1 RA therapy
- Reassess A1c in 3 months and continue intensifying until individualized glycemic target achieved